Pfizer Secures Up to $1.5 Billion From Blackstone to Advance Monthly GLP-1 Programme
Pfizer (NYSE: PFE) and Blackstone Life Sciences agreed on a $1.5 billion co-funding deal for berobenatide, a GLP-1 receptor agonist for weight management. Blackstone will cover development costs through 2028, with potential milestone payments. Pfizer retains control of the program.
How this was made

The 30-second read
Why it matters
The $1.5 billion co‑funding reduces Pfizer's exposure to development costs and may accelerate timelines, potentially boosting near‑term revenue guidance.
Market read
A sizable, first‑report financing deal that could positively affect Pfizer's stock and the broader biotech financing landscape.
What to watch
Milestone‑based payments to Blackstone could dilute future upside if commercial targets are not met.
Background
Pfizer's obesity franchise is a strategic priority; GLP‑1 drugs have become a high‑growth area after successes like Wegovy.
Ticker impact
Pfizer announced a new co‑funding agreement with Blackstone providing up to $1.5 billion for its monthly GLP‑1 obesity drug program.
upward pressure as investors view the capital infusion as de‑risking the GLP‑1 program.
Large, previously undisclosed capital commitment directly benefits Pfizer's pipeline and may improve earnings outlook.
Market effects
Strengthens the biotech/obesity‑therapy sector by showing investor confidence in GLP‑1 approaches.
U.S. pharma stocks may see modest gains as the deal highlights financing avenues for pipeline development.
Highlights growing private‑equity involvement in large‑scale drug development worldwide.
Counterpoint
The funding could signal that Pfizer needs external capital, hinting at cash‑flow pressures or higher risk in the GLP‑1 program.
Key entities
- companyPfizer Inc.
U.S. pharmaceutical giant developing the GLP‑1 drug berobenatide.
- investment_firmBlackstone Life Sciences
Private‑equity arm providing the co‑funding and milestone payments.



